Ablation of heart tissue for atrial fibrillation

Interventions for arrhythmia
Number of report

Ask the expert

(we accept only company emails)

The report presents summary of reimbursement situation for heart tissue ablation methods to treat atrial fibrillation.

Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations). 

Different types of ablation methods are considered in the report, including radiofrequency ablation, cryoablation, microwave ablation.

Report includes information about three types of access to perform ablation:

  • Transluminal access
  • Percutaneous thoracoscopic access
  • Open access

Procedures using transluminal and percutaneous thoracoscopic access are analyzed as stand-alone procedures. Ablation using open access is analyzed in conjunction with open heart surgery (coronary artery bypass grafting or aortic valve replacement).

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of devices for ablation of heart tissue include:

  • Abbott (TactiCath Quartz ablation catheter, FlexAbility ablation catheter)
  • Access Point Technologies EP (Ablation catheters)
  • AFreeze (CoolLoop catheter)
  • AtriCure (Isolator Synergy Clamps, Isolator Synergy Access Clamp, COBRA Fusion 150 and 50 Ablation System, EPi-Sense Coagulation Device, Subtle Cannula, Coolrail Linear Pen, Isolator Linear Pen, Isolator Transpolar Pen)
  • Baylis Medical (NRG RF Transseptal Needle)
  • Biosense Webster (CELSIUS Diagnostic/Ablation Deflectable Tip Catheter, NAVISTAR Catheter, THERMOCOOL Catheter)
  • Biotronik (AlCath Gold FullCircle Ablation catheter, AlCath Flutter Gold Ablation catheter, AlCath Flux eXtra Gold Ablation catheter).
  • Boston Scientific (BLAZER PRIME Temperature Ablation Catheter, BLAZER II Temperature Ablation Catheter Family, BLAZER Open Irrigated Temperature Ablation Catheter, INTELLANAV OPEN-IRRIGATED, INTELLATIP MIFI OPEN-IRRIGATED Ablation Catheter, INTELLATIP MIFI XP Temperature Ablation Catheter)
  • CathRx (Khelix Ablation catheter)
  • Integer Holdings Corporation (EP ablation catheters)
  • Lepu Medical (Eel Cath EP ablation catheter)
  • MicroPort (FireMagic, FireMagic 3D)
  • Medtronic (RF Marinr MC catheter, RF Contactr ablation catheter, RF Enhancr II catheter, RF Conductr MC catheter)
  • OSCOR (Destine Reach)
  • Osypka Medical (Cerablate easy steerable ablation catheter, Cerablate cool steerable ablation catheter, Cerablate flutter steerable ablation catheter)

Table of content

1.    Introduction and summary
2.    Executive summary table
3.    Contents
4.    Methodology
5.    Reimbursement analysis in Austria

5.1.    Overview of the reimbursement system
5.2.    Reimbursement for ablation of heart tissue for atrial fibrillation
5.2.1.    Procedure coding
5.2.2.    Diagnosis coding
5.2.3.    Payment mechanism and reimbursement tariffs
5.2.4.    Health technology assessments by LBI-HTA
6.    Reimbursement analysis in Belgium
6.1.    Overview of the reimbursement system
6.2.    Reimbursement for ablation of heart tissue for atrial fibrillation
6.2.1.    Procedure coding
6.2.2.    Diagnosis coding
6.2.3.    Payment mechanism and reimbursement tariffs
6.2.4.    Policy considerations    Health technology assessments by KCE
7.    Reimbursement analysis in Denmark
7.1.    Overview of the reimbursement system
7.2.    Reimbursement for ablation of heart tissue for atrial fibrillation
7.2.1.    Procedure coding 
7.2.2.    Diagnosis coding
7.2.3.    Payment mechanism and reimbursement tariffs
8.    Reimbursement analysis in England
8.1.    Overview of the reimbursement system
8.2.    Reimbursement for ablation of heart tissue for atrial fibrillation
8.2.1.    Procedure coding 
8.2.2.    Diagnosis coding
8.2.3.    Payment mechanism and reimbursement tariffs
8.2.4.    Policy considerations    Specifics of commissioning of the procedure    Health technology assessments by NICE
9.    Reimbursement analysis in France
9.1.    Overview of the reimbursement system
9.2.    Reimbursement for ablation of heart tissue for atrial fibrillation
9.2.1.    Procedure coding 
9.2.2.    Diagnosis coding
9.2.3.    Payment mechanism and reimbursement tariffs
9.2.4.    Policy considerations by HAS
10.    Reimbursement analysis in Germany
10.1.    Overview of the reimbursement system
10.2.    Reimbursement for ablation of heart tissue for atrial fibrillation
10.2.1.    Procedure coding 
10.2.2.    Diagnosis coding
10.2.3.    Payment mechanism and reimbursement tariffs
11.    Reimbursement analysis in Italy
11.1.    Overview of the reimbursement system
11.2.    Reimbursement for ablation of heart tissue for atrial fibrillation
11.2.1.    Procedure coding at national level
11.2.2.    Procedure coding at regional level (Emilia-Romagna, Lombardy, Veneto regions)
11.2.3.    Diagnosis coding
11.2.4.    Payment mechanism and reimbursement tariffs at national level
11.2.5.    Payment mechanism and reimbursement tariffs at regional level
12.    Reimbursement analysis in the Netherlands
12.1.    Overview of the reimbursement system
12.2.    Reimbursement for ablation of heart tissue for atrial fibrillation
12.2.1.    Procedure coding 
12.2.2.    Diagnosis coding
12.2.3.    Payment mechanism and reimbursement tariffs
13.    Reimbursement analysis in Norway
13.1.    Overview of the reimbursement system
13.2.    Reimbursement for ablation of heart tissue for atrial fibrillation
13.2.1.    Procedure coding 
13.2.2.    Diagnosis coding
13.2.3.    Payment mechanism and reimbursement tariffs
13.2.4.    Policy considerations 
14.    Reimbursement analysis in Sweden
14.1.    Overview of the reimbursement system
14.2.    Reimbursement for ablation of heart tissue for atrial fibrillation
14.2.1.    Procedure coding 
14.2.2.    Diagnosis coding
14.2.3.    Payment mechanism and reimbursement tariffs
14.2.4.    Policy considerations 
15.    Reimbursement analysis in Switzerland
15.1.    Overview of the reimbursement system
15.2.    Reimbursement for ablation of heart tissue for atrial fibrillation
15.2.1.    Procedure coding 
15.2.2.    Diagnosis coding
15.2.3.    Payment mechanism and reimbursement tariffs
15.2.4.    Policy considerations
16.    Disclaimer


Nov 2022

In November 2022, the National Board of Health and Welfare released the Swedish version of the NordDRG system to come into force in January 2023, including the list of DRG codes, names, and cost-weights. A total of 77 new DRGs will be implemented. Key new DRGs were introduced in cardiovascular, gastrointestinal, and endoscopy fields, also for breast reconstruction and bone-anchored hearing implants.

Read more


Sep 2022

The HTA body of the Tuscany Regional Healthcare issues three types of documents: full HTA reports, rapid HTA reports, and motivational forms. With regional decree 15937 of August 4, 2022, Tuscany Regional Healthcare has published assessments of six medical devices in various therapeutic areas, such as cardiovascular and peripheral vascular areas, neurovascular procedures, gastroenterology, and dermatology.

Read more


Aug 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With regional decree 13241 of July 4, 2022, Tuscany Regional Healthcare has published assessments of three medical devices in the cardiovascular area.

Read more


Jun 2021

In May 2021, the National Institute for Health and Care Excellence (NICE) published five new Interventional Procedure Guidance (ex-situ machine perfusion for extracorporeal preservation of lungs for transplant, transvaginal laser therapy for stress urinary incontinence and for urogenital atrophy, electrohydraulic lithotripsy for difficult-to-treat bile duct stones, and permanent His-bundle pacemaker for heart failure), one new Medical Technologies Guidance (UroLift for benign prostatic hyperplasia), and two new Medtech Innovation Briefings (Axonics sacral neuromodulation system for faecal incontinence and KODEX-EPD for cardiac imaging during ablation of arrhythmias). Also, three clinical guidelines and two Medical Technologies Guidance were updated.

Read more


May 2021

In April 2021, the National Institute for Health and Care Excellence (NICE) published three new Interventional Procedure Guidance (repetitive short-pulse transscleral cyclophotocoagulation for glaucoma, deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults, and Melphalan chemosaturation for primary or metastatic cancer in the liver) and two Medtech Innovation Briefings (microINR for anticoagulation therapy and RenalSense Clarity RMS for acute kidney injury), and two clinical guidelines (for atrial fibrillation and chronic pain in over 16s).

Read more
(we accept only company emails)